- Home
- ABOS vs CDXS Comparison
ABOS vs CDXS Comparison
Compare ABOS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CDXS
- Stock Information
- Founded
- ABOS 1996
- CDXS 2002
- Country
- ABOS United States
- CDXS United States
- Employees
- ABOS N/A
- CDXS N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- ABOS Health Care
- CDXS Industrials
- Exchange
- ABOS Nasdaq
- CDXS Nasdaq
- Market Cap
- ABOS 166.4M
- CDXS 204.6M
- IPO Year
- ABOS 2021
- CDXS 2010
- Fundamental
- Price
- ABOS $2.22
- CDXS $2.74
- Analyst Decision
- ABOS Strong Buy
- CDXS Buy
- Analyst Count
- ABOS 4
- CDXS 3
- Target Price
- ABOS $9.00
- CDXS $10.50
- AVG Volume (30 Days)
- ABOS 185.7K
- CDXS 317.5K
- Earning Date
- ABOS 08-13-2024
- CDXS 10-31-2024
- Dividend Yield
- ABOS N/A
- CDXS N/A
- EPS Growth
- ABOS N/A
- CDXS N/A
- EPS
- ABOS N/A
- CDXS N/A
- Revenue
- ABOS N/A
- CDXS $60,890,000.00
- Revenue This Year
- ABOS N/A
- CDXS N/A
- Revenue Next Year
- ABOS N/A
- CDXS $1.68
- P/E Ratio
- ABOS N/A
- CDXS N/A
- Revenue Growth
- ABOS N/A
- CDXS N/A
- 52 Week Low
- ABOS $1.81
- CDXS $1.45
- 52 Week High
- ABOS $5.76
- CDXS $4.91
- Technical
- Relative Strength Index (RSI)
- ABOS 32.70
- CDXS 37.29
- Support Level
- ABOS $2.73
- CDXS $2.72
- Resistance Level
- ABOS $2.92
- CDXS $3.17
- Average True Range (ATR)
- ABOS 0.19
- CDXS 0.16
- MACD
- ABOS -0.06
- CDXS -0.01
- Stochastic Oscillator
- ABOS 7.17
- CDXS 12.24
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.